Page last updated: 2024-08-24

gemcitabine and Hemangioendothelioma, Epithelioid

gemcitabine has been researched along with Hemangioendothelioma, Epithelioid in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Biskup, S; Hinterleitner, C; Hinterleitner, M; Krumm, P; Lauer, UM; Mattern, S; Schmidt, M; Schulze, M; Singer, S; Zender, L	1
Fitzpatrick, FC; Sabile, JMG; Skelton, MR; Stump, MS	1
Bartolazzi, A; D'Arino, A; Federico, A; Magri, F; Muscianese, M; Pigliacelli, F; Pranteda, G	1
Hartmann, JT; Horger, M; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; von Weyhern, C	1

Reviews

2 review(s) available for gemcitabine and Hemangioendothelioma, Epithelioid

Article	Year
NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9 Topics: Carcinoma, Non-Small-Cell Lung; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Lung Neoplasms; Mutation, Missense; Receptor, Notch3	2023
The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature. Dermatologic therapy, 2018, Volume: 31, Issue:6 Topics: Adolescent; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Deoxycytidine; Foot; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Soft Tissue Neoplasms; Treatment Outcome	2018

Article

Year

NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.

Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

Topics: Carcinoma, Non-Small-Cell Lung; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Lung Neoplasms; Mutation, Missense; Receptor, Notch3

2023

The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature.

Dermatologic therapy, 2018, Volume: 31, Issue:6

Topics: Adolescent; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Deoxycytidine; Foot; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Soft Tissue Neoplasms; Treatment Outcome

2018

Other Studies

2 other study(ies) available for gemcitabine and Hemangioendothelioma, Epithelioid

Article	Year
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel. JCO oncology practice, 2021, Volume: 17, Issue:2 Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans	2021
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma. Anti-cancer drugs, 2009, Volume: 20, Issue:1 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Doxorubicin; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Scapula; Time Factors; Treatment Outcome	2009

Article

Year

Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel.

JCO oncology practice, 2021, Volume: 17, Issue:2

Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans

2021

Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.

Anti-cancer drugs, 2009, Volume: 20, Issue:1

Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Doxorubicin; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Scapula; Time Factors; Treatment Outcome

2009